The Impact of COVID-19 on Cancer

References

• PascarellaG, StrumiaA, PiliegoC, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020;288(2):192–206. doi:10.1111/joim.1309132348588
   PubMed Web of Science ®Google Scholar
• Fang Z, Fang Y, Kang W, et al. Clinical characteristics of Coronavirus Disease 2019 (COVID-19): an updated systematic review. medRxiv. 2020. Available from:https://www.medrxiv.org/content/10.1101/2020.03.07.20032573v2. Accessed 98, 2021.
   Google Scholar
• Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26(7):1017–1032. doi:10.1038/s41591-020-0968-3
   Google Scholar
• National Health Commission of the People’s Republic of China. COVID-19 is Included in the Management of Legal Infectious Diseases; 120, 2020.
   Google Scholar
• WHO. COVID-19 Weekly Epidemiological Update; 13, 2020.
   Google Scholar
• DisisML. Oncology and COVID-19. JAMA. 2020;324(12):1141–1142. doi:10.1001/jama.2020.1694532960256
   PubMed Web of Science ®Google Scholar
• JonesD, NealRD, DuffySRG, ScottSE, WhitakerKL, BrainK. Impact of the COVID-19 pandemic on the symptomatic diagnosis of cancer: the view from primary care. Lancet Oncol. 2020;21(6):748–750. doi:10.1016/S1470-2045(20)30242-432359404
   PubMed Web of Science ®Google Scholar
• TagliamentoM, LambertiniM, GenovaC, et al. Call for ensuring cancer care continuity during COVID-19 pandemic. ESMO Open. 2020;5(3):e000783. doi:10.1136/esmoopen-2020-00078332381594
   PubMed Web of Science ®Google Scholar
• IslamJY, Camacho-RiveraM, VidotDC. Examining COVID-19 preventive behaviors among cancer survivors in the United States: an analysis of the COVID-19 impact survey. Cancer Epidemiol Biomarkers Prev. 2020;29(12):2583–2590. doi:10.1158/1055-9965.EPI-20-080132978173
   PubMed Web of Science ®Google Scholar
• ChallinorJM, AlqudimatMR, TeixeiraTOA, OldenmengerWH. Oncology nursing workforce: challenges, solutions, and future strategies. Lancet Oncol. 2020;21(12):e564–e574. doi:10.1016/S1470-2045(20)30605-733212044
   PubMed Web of Science ®Google Scholar
• BurkiTK. Burnout among cancer professionals during COVID-19. Lancet Oncol. 2020;21(11):1402. doi:10.1016/S1470-2045(20)30584-232979982
   PubMed Web of Science ®Google Scholar
• BakounyZ, PaciottiM, SchmidtAL, LipsitzSR, ChoueiriTK, TrinhQ-D. Cancer screening tests and cancer diagnoses during the COVID-19 pandemic. JAMA Oncol. 2021;7(3):458. doi:10.1001/jamaoncol.2020.760033443549
   PubMed Web of Science ®Google Scholar
• MaringeC, SpicerJ, MorrisM, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 2020;21(8):1023–1034. doi:10.1016/S1470-2045(20)30388-032702310
   PubMed Web of Science ®Google Scholar
• LiangW, GuanW, ChenR, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–337. doi:10.1016/S1470-2045(20)30096-632066541
   PubMed Web of Science ®Google Scholar
• JohnsonBA, WaddimbaAC, OgolaGO, FleshmanJWJr, PreskittJT. A systematic review and meta-analysis of surgery delays and survival in breast, lung and colon cancers: implication for surgical triage during the COVID-19 pandemic. Am J Surg. 2020(2021):331–318.
   Google Scholar
• SudA, JonesME, BroggioJ, et al. Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic. Ann Oncol. 2020;31(8):1065–1074.10. doi:10.1016/j.annonc.2020.05.00932442581
   PubMed Web of Science ®Google Scholar
• RiemannS, SpeckI, GerstackerK, BeckerC, KnopfA. Collateral damage of the COVID-19 pandemic: an alarming decline in critical procedures in otorhinolaryngology in a German university hospital. Eur Arch Otorhinolaryngol. 2020;278(9):3417–3423.33320294
   PubMed Web of Science ®Google Scholar
• ZhangL, ZhuF, XieL, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020;31(7):894–901. doi:10.1016/j.annonc.2020.03.29632224151
   PubMed Web of Science ®Google Scholar
• Al-ShamsiHO, AlhazzaniW, AlhuraijiA, et al. A practical approach to the management of cancer patients during the novel Coronavirus Disease 2019 (COVID-19) pandemic: an International Collaborative Group. Oncologist. 2020;25(6):e936–e945. doi:10.1634/theoncologist.2020-021332243668
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Coronavirus Disease 2019 (COVID-19) resources for the cancer care community. (2020 Version 1). Available from:www.nccn.org/covid-19/default.aspx. Accessed 825, 2021.
   Google Scholar
• LancmanG, MascarenhasJ, Bar-NatanM. Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia. J Hematol Oncol. 2020;13(1):131. doi:10.1186/s13045-020-00968-133008453
   PubMed Web of Science ®Google Scholar
• CameronBJ, GerryAB, DukesJ, et al. Identification of a titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med. 2013;5(197):197ra103. doi:10.1126/scitranslmed.3006034
   PubMed Web of Science ®Google Scholar
• LinetteGP, StadtmauerEA, MausMV, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122(6):863–871. doi:10.1182/blood-2013-03-49056523770775
   PubMed Web of Science ®Google Scholar
• MorganRA, ChinnasamyN, Abate-DagaD, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013;36(2):133–151. doi:10.1097/CJI.0b013e318282990323377668
   PubMed Web of Science ®Google Scholar
• ZhaoZ, ZhengL, ChenW, WengW, SongJ, JiJ. Delivery strategies of cancer immunotherapy: recent advances and future perspectives. J Hematol Oncol. 2019;12(1):126. doi:10.1186/s13045-019-0817-331779642
   PubMed Web of Science ®Google Scholar
• BonifantCL, JacksonHJ, BrentjensRJ, CurranKJ. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics. 2016;3:16011. doi:10.1038/mto.2016.1127626062
   PubMed Web of Science ®Google Scholar
• LeeDW, GardnerR, PorterDL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188–195. doi:10.1182/blood-2014-05-55272924876563
   PubMed Web of Science ®Google Scholar
• GourdE. Lung cancer control in the UK hit badly by COVID-19 pandemic. Lancet Oncol. 2020;21(12):1559. doi:10.1016/S1470-2045(20)30691-433189158
   PubMed Web of Science ®Google Scholar
• ZhangYJ, YangWJ, LiuD, et al. COVID-19 and early-stage lung cancer both featuring ground-glass opacities: a propensity score-matched study. Transl Lung Cancer Res. 2020;9(4):1516–1527. doi:10.21037/tlcr-20-89232953523
   PubMed Web of Science ®Google Scholar
• WestbladeLF, BrarG, PinheiroLC, et al. SARS-CoV-2 viral load predicts mortality in patients with and without cancer who are hospitalized with COVID-19. Cancer Cell. 2020;38(5):661–671.e2. doi:10.1016/j.ccell.2020.09.00732997958
   PubMed Web of Science ®Google Scholar
• SchreiberRD, OldLJ, SmythMJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331(6024):1565–1570. doi:10.1126/science.120348621436444
   PubMed Web of Science ®Google Scholar
• GiovannucciE, HarlanDM, ArcherMC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33(7):1674–1685. doi:10.2337/dc10-066620587728
   PubMed Web of Science ®Google Scholar
• KitsisRN, RiquelmeJA, LavanderoS. Heart disease and cancer: are the two killers colluding?Circulation. 2018;138(7):692–695. doi:10.1161/CIRCULATIONAHA.118.03390730359137
   PubMed Web of Science ®Google Scholar
• ChenW, ZhengR, BaadePD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• Lauby-SecretanB, ScocciantiC, LoomisD, GrosseY, BianchiniF, StraifK; International Agency for Research on Cancer Handbook Working Group. Body fatness and cancer–viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794–798. doi:10.1056/NEJMsr160660227557308
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Why People with Cancer are More Likely to Get Infections; 32020. Accessed 814, 2020.
   Google Scholar
• WangQ, BergerNA, XuR. Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection. JAMA Oncol. 2020;10:e206178.
   Google Scholar
• Di LorenzoG, Di TrolioR, KozlakidisZ, et al. COVID 19 therapies and anti-cancer drugs: a systematic review of recent literature. Crit Rev Oncol Hematol. 2020;152:102991. doi:10.1016/j.critrevonc.2020.10299132544802
   PubMed Web of Science ®Google Scholar
• LeeLYW, CazierJB, StarkeyT, BriggsSEW, ArnoldR, BishtV. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020;21(10):1309–1316. doi:10.1016/S1470-2045(20)30442-332853557
   PubMed Web of Science ®Google Scholar
• JeeJ, FooteMB, LumishM, et al. Chemotherapy and COVID-19 outcomes in patients with cancer. J Clin Oncol. 2020;38(30):3538–3546. doi:10.1200/JCO.20.0130732795225
   PubMed Web of Science ®Google Scholar
• KongQ, XiangZ, WuY, GuY, GuoJ, GengF. Analysis of the susceptibility of lung cancer patients to SARS-CoV-2 infection. Mol Cancer. 2020;19(1):80. doi:10.1186/s12943-020-01209-232345328
   PubMed Web of Science ®Google Scholar
• TutuncuogluB, CakirM, BatraJ, et al. The landscape of human cancer proteins targeted by SARS-CoV-2. Cancer Discov. 2020;10(7):916–921. doi:10.1158/2159-8290.CD-20-055932444466
   PubMed Web of Science ®Google Scholar
• LiW, MooreMJ, VasilievaN, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–454. doi:10.1038/nature0214514647384
   PubMed Web of Science ®Google Scholar
• HouY, PengC, YuM, et al. Angiotensin-converting enzyme 2 (ACE2) proteins of different bat species confer variable susceptibility to SARS-CoV entry. Arch Virol. 2010;155(10):1563–1569. doi:10.1007/s00705-010-0729-620567988
   PubMed Web of Science ®Google Scholar
• HattermannK, MüllerMA, NitscheA, WendtS, Donoso MantkeO, NiedrigM. Susceptibility of different eukaryotic cell lines to SARS-coronavirus. Arch Virol. 2005;150(5):1023–1031. doi:10.1007/s00705-004-0461-115645376
   PubMed Web of Science ®Google Scholar
• RenP, GongC, MaS. Evaluation of COVID-19 based on ACE2 expression in normal and cancer patients. Open Med. 2020;15(1):613–622. doi:10.1515/med-2020-0208
   Web of Science ®Google Scholar
• ChaiP, YuJ, GeS, JiaR, FanX. Genetic alteration, RNA expression, and DNA methylation profiling of coronavirus disease 2019 (COVID-19) receptor ACE2 in malignancies: a pan-cancer analysis. J Hematol Oncol. 2020;13(1):43. doi:10.1186/s13045-020-00883-532366279
   PubMed Web of Science ®Google Scholar
• YangJ, LiH, HuS, ZhouY. ACE2 correlated with immune infiltration serves as a prognostic biomarker in endometrial carcinoma and renal papillary cell carcinoma: implication for COVID-19. Aging. 2020;12(8):6518–6535. doi:10.18632/aging.10310032339157
   PubMedGoogle Scholar
• EhrlichM. DNA hypomethylation in cancer cells. Epigenomics. 2009;1(2):239–259. doi:10.2217/epi.09.3320495664
   PubMed Web of Science ®Google Scholar
• WangXS. Angiotensin-converting enzyme 2 connects COVID-19 with cancer and cancer immunotherapy. World J Gastrointest Oncol. 2021;13(3):157–160. doi:10.4251/wjgo.v13.i3.15733738043
   PubMed Web of Science ®Google Scholar
• PathaniaAS, PrathipatiP, AbdulBA, et al. COVID-19 and cancer comorbidity: therapeutic opportunities and challenges. Theranostics. 2021;11(2):731–753. doi:10.7150/thno.5147133391502
   PubMed Web of Science ®Google Scholar
• National Health Commission of the People’s Republic of China. Diagnosis and Treatment Plan of COVID-19 (8th Trial Version); 819, 2020.
   Google Scholar
• GarassinoMC, WhisenantJG, HuangLC. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020;21(7):914–922. doi:10.1016/S1470-2045(20)30314-432539942
   PubMed Web of Science ®Google Scholar
• GalluzziL, BuqueA, KeppO, ZitvogelL, KroemerG. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28(6):690–714. doi:10.1016/j.ccell.2015.10.01226678337
   PubMed Web of Science ®Google Scholar
• Dexamethasone for COVID-19. preliminary findings. Drug Ther Bull. 2020;58(9):133. doi:10.1136/dtb.2020.00004532690491
   PubMedGoogle Scholar
• VargasAJ, HarrisCC. Biomarker development in the precision medicine era: lung cancer as a case study. Nat Rev Cancer. 2016;16(8):525–537. doi:10.1038/nrc.2016.5627388699
   PubMed Web of Science ®Google Scholar
• TurnquistC, RyanBM, HorikawaI, HarrisBT, HarrisCC. Cytokine storms in cancer and COVID-19. Cancer Cell. 2020;38(5):598–601. doi:10.1016/j.ccell.2020.09.01933038939
   PubMed Web of Science ®Google Scholar
• HamIH, OhHJ, JinH, et al. Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer. Mol Cancer. 2019;18(1):68. doi:10.1186/s12943-019-0972-830927911
   PubMed Web of Science ®Google Scholar
• ChallenorS, TuckerD. SARS-CoV-2-induced remission of Hodgkin lymphoma. Br J Haematol. 2021;192(3):415. doi:10.1111/bjh.1711633386647
   PubMed Web of Science ®Google Scholar
• FleuryME, FarnerAM, UngerJM. Association of the COVID-19 outbreak with patient willingness to enroll in cancer clinical trials. JAMA Oncol. 2021;7(1):131–132. doi:10.1001/jamaoncol.2020.574833180102
   PubMed Web of Science ®Google Scholar
•  Sheridan K. U.S. biotechs fear the coronavirus outbreak will delay their China-based research. Available from: https://www.statnews.com/2020/02/11/biotechs-fear-coronavirus-will-delay-china-based-research/. Accessed 211, 2020.
   Google Scholar
• BurkiTK. Cuts in cancer research funding due to COVID-19. Lancet Oncol. 2021;22(1):e6. doi:10.1016/S1470-2045(20)30749-X33341123
   PubMed Web of Science ®Google Scholar
• Ribas A, Leng G.Clinical research slows as COVID-19 surges. Cancer Discov. 2020;10(5):630. doi:10.1158/2159-8290.
   Web of Science ®Google Scholar
• FadaviP, HoushyariM, Yousefi KashiAS, et al. Review on the oncology practice in the midst of COVID-19 crisis: the challenges and solutions. Asian Pac J Cancer Prev. 2021;22(1):19–24. doi:10.31557/APJCP.2021.22.1.1933507674
   PubMedGoogle Scholar
• PennellNA, DillmonM, LevitLA, et al. American society of clinical oncology road to recovery report: learning from the COVID-19 experience to improve clinical research and cancer care. J Clin Oncol. 2021;39(2):155–169. doi:10.1200/JCO.20.0295333290128
   PubMed Web of Science ®Google Scholar
• TzengCD, TeshomeM, KatzMHG, et al. Cancer surgery scheduling during and after the COVID-19 first wave: the MD Anderson cancer center experience. Ann Surg. 2020;272(2):e106–e111. doi:10.1097/SLA.000000000000409232675511
   PubMed Web of Science ®Google Scholar
• ButlerJ, FinleyC, NorellCH, et al. New approaches to cancer care in a COVID-19 world. Lancet Oncol. 2020;21(7):e339–e340. doi:10.1016/S1470-2045(20)30340-532615112
   PubMed Web of Science ®Google Scholar
• AACR Board of Directors. AACR calls on congress to take immediate action against COVID-19 and protect patients with cancer during the pandemic. Cancer Discov. 2020;10(6):771–774. doi:10.1158/2159-8290.CD-20-044932295764
   PubMed Web of Science ®Google Scholar
• GyawaliB, PoudyalBS, EisenhauerEA. Covid-19 pandemic—an opportunity to reduce and eliminate low-value practices in oncology?JAMA Oncol. 2020;6(11):1693. doi:10.1001/jamaoncol.2020.240432614374
   PubMed Web of Science ®Google Scholar
• GlobalData Healthcare. Clinical trial disruption due to Covid-19 has begun to slow. Available from:https://www.clinicaltrialsarena.com/comment/clinical-trial-disruption-slowing/. Accessed August 30, 2021.
   Google Scholar